Newest figures come from the 10-Q for Q1 FY2026, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CYCCP SEC filings page.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) reported $747K in revenue for fiscal year 2025, up 1637.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cyclacel remains a development-stage business: modest revenue sits beside operating losses, negative cash flow, and financing-dependent balance-sheet support.
In FY2025, positive net income of$2.998M coexisted with operating cash flow of-$4.77M , so accounting earnings did not fund operations. Financing cash flow supplied$5.264M , indicating that reported earnings and the cash needed to run the business remain disconnected.
The business is still spending more than it generates from operations: FY2025 revenue was
Liabilities fell
Financial Health Signals
We do not publish a peer-relative financial health score for Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
For every $1 of reported earnings, Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock used $1.59 of operating cash (-$4.8M OCF vs $3.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock reported an operating loss of $8.4M against $62K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock generated $743K in revenue in Q1 2026.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock's EBITDA was -$245K in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock reported a net loss of $197K in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock earned -$0.04 per diluted share (EPS) in Q1 2026.
Cash & Balance Sheet
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock recorded an outflow of $279K in free cash flow in Q1 2026, representing a cash shortfall after capex.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock held $3.3M in cash as of Q1 2026; no long-term debt figure is on record for that period.
Not reported for Q1 2026.
Margins & Returns
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock's operating margin was -33.1% in Q1 2026, reflecting core business profitability.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock's net profit margin was -26.5% in Q1 2026, showing the share of revenue converted to profit.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock's quarterly ROE was -2.9% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is down 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.0 percentage points.
Not reported for Q1 2026.
Capital Allocation
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock invested $1K in capex in Q1 2026, funding long-term assets and infrastructure.
Not reported for Q1 2026.
Not reported for Q1 2026.
CYCCP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $743K | N/A | $81K+710.0% | N/A | N/A | $0-100.0% | $10K-37.5% | $4K-98.9% |
| R&D Expenses | N/A | N/A | $5K-99.5% | $68K-96.6% | $822K-70.7% | $880K-75.0% | $950K-81.9% | $2.0M-57.2% |
| SG&A Expenses | $389K-90.8% | $1.3M+31.9% | $1.0M-18.8% | $1.2M-23.1% | $4.2M+166.4% | $948K-49.4% | $1.2M-23.9% | $1.6M+3.2% |
| Operating Income | -$246Kn/m | N/A | -$992Kn/m | -$1.3Mn/m | -$4.2Mn/m | -$1.8Mn/m | -$2.2Mn/m | -$3.6Mn/m |
| EBITDA | -$245K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $9K+50.0% | N/A | $9K+12.5% | $2Kn/m | $6K+200.0% | $30K | $8K | -$28K |
| Income Tax | $30K | N/A | N/A | $2Kn/m | N/A | $1.2Mn/m | -$210Kn/m | -$412Kn/m |
| Net Income | -$197Kn/m | -$611Kn/m | -$988Kn/m | -$1.3Mn/m | -$81Kn/m | -$3.1Mn/m | -$2.0Mn/m | -$3.3Mn/m |
| EPS (Basic) | -$0.04 | N/A | -$1.31 | -$0.98 | $0.00n/m | N/A | -$43.80 | -$172.18 |
| EPS (Diluted) | -$0.04 | N/A | -$1.31 | -$0.98 | $0.00n/m | N/A | -$43.80 | -$172.18 |
| Diluted Shares (Avg) | 5M | N/A | 2M | N/A | 365,231 | N/A | 44,681 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
CYCCP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.6M+102.6% | $8.2M+99.9% | $8.2M+51.6% | $4.4M-46.3% | $3.7M-39.4% | $4.1M-53.5% | $5.4M-56.9% | $8.2M-51.8% |
| Current Assets | $5.6M+51.4% | $6.3M+70.3% | $6.4M+31.2% | $4.4M-43.1% | $3.7M-23.2% | $3.7M-50.6% | $4.9M-55.8% | $7.7M-49.6% |
| Cash & Equivalents | $3.3M-3.2% | $3.5M+11.7% | $3.8M+28.7% | $4.3M-28.7% | $3.5M+23.3% | $3.1M-7.1% | $3.0M-49.8% | $6.0M-41.0% |
| Inventory | $947K | $1.4M | $1.4M | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.2M | $1.3M | $725K | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $1.6M | $1.6M | $1.6M | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $804K+19.6% | $1.3M-78.6% | $1.1M-83.3% | $770K-89.3% | $672K-92.0% | $6.3M-23.5% | $6.4M-22.5% | $7.2M+3.8% |
| Current Liabilities | $796K+20.1% | $1.3M-78.7% | $1.0M-84.2% | $760K-89.4% | $663K-92.1% | $6.3M-23.2% | $6.4M-22.1% | $7.2M+4.7% |
| Non-Current Liabilities | $8K-11.1% | $11Kn/m | $60Kn/m | $10K+100.0% | $9K-57.1% | $0-100.0% | $0-100.0% | $5K-92.4% |
| Total Equity | $6.8M+120.8% | $6.8Mn/m | $7.1Mn/m | $3.6M+263.5% | $3.1Mn/m | -$2.2M-458.2% | -$970K-122.6% | $999K-85.0% |
| Retained Earnings | -$454.6Mn/m | -$454.4Mn/m | -$444.3Mn/m | -$441.8Mn/m | -$440.5Mn/m | -$439.5Mn/m | -$436.4Mn/m | -$434.5Mn/m |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Long-Term Debt.
CYCCP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$278Kn/m | -$33Kn/m | -$434Kn/m | -$1.1Mn/m | -$3.2Mn/m | -$1.4Mn/m | -$3.1Mn/m | -$3.1Mn/m |
| Depreciation & Amortization | $1K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock-Based Compensation | $1K-99.9% | N/A | $6K-94.4% | $7K-96.3% | $1.7M+720.7% | N/A | $107K-72.6% | $189K-47.4% |
| Capital Expenditures | $1K | N/A | N/A | N/A | N/A | N/A | $0n/m | N/A |
| Free Cash Flow | -$279K | N/A | N/A | N/A | N/A | N/A | -$3.1Mn/m | N/A |
| Investing Cash Flow | -$1K | N/A | N/A | N/A | N/A | N/A | $0n/m | N/A |
| Financing Cash Flow | $105K-97.1% | -$259K-116.1% | -$3Kn/m | $1.9M-70.1% | $3.6Mn/m | $1.6M+61.5% | -$1Kn/m | $6.3Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CYCCP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -33.1% | N/A | -1224.7% | N/A | N/A | N/A | -21770.0% | -91100.0% |
| Net Margin | -26.5% | N/A | -1219.8% | N/A | N/A | N/A | -19570.0% | -81425.0% |
| Return on Equity | -2.9%-0.3pp | -8.9% | -13.9% | -36.3%+289.7pp | -2.6% | N/A | N/A | -326.0%-244.4pp |
| Return on Assets | -2.6%-0.4pp | -7.5%+67.1pp | -12.1%+24.3pp | -29.9%+9.8pp | -2.2%+45.6pp | -74.6%-14.7pp | -36.4%+11.9pp | -39.8%-7.7pp |
| Current Ratio | 7.06+1.5x | 4.70+4.1x | 6.43+5.7x | 5.77+4.7x | 5.60+5.0x | 0.59-0.3x | 0.77-0.6x | 1.07-1.2x |
| Liabilities-to-Equity | 0.12-0.1x | 0.20 | 0.15 | 0.21-7.0x | 0.22 | N/A | N/A | 7.20+6.2x |
| Asset Turnover | 0.10 | N/A | 0.010.0x | N/A | N/A | 0.000.0x | 0.000.0x | 0.000.0x |
| FCF Margin | -37.5% | N/A | N/A | N/A | N/A | N/A | -30670.0% | N/A |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock CYCCP | FY2025 | $747K | $3.0M | N/A | N/A | — |
| Xilio Therapeutics, Inc. XLO | FY2025 | $43.8M | -$35.0M | -80.0% | $53.4M | 76/100 |
| Alaunos Therapeutics, Inc. TCRT | FY2025 | $5K | -$4.2M | N/A | $7.0M | — |
| SELLAS Life Sciences Group, Inc. SLS | FY2025 | N/A | -$26.9M | N/A | $2.8B | — |
| Prelude Therapeutics Incorporated PRLD | FY2025 | $12.1M | -$99.5M | N/A | $258.5M | 73/100 |
| InflaRx N.V. IFRX | FY2025 | $34K | -$53.6M | N/A | $153.3M | — |
Where Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Ranks
Frequently Asked Questions
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) reported $747K in total revenue for fiscal year 2025. This represents a 1637.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) revenue grew by 1637.2% year-over-year, from $43K to $747K in fiscal year 2025.
Yes, Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) reported a net income of $3.0M in fiscal year 2025.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) had EBITDA of -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) has a return on equity of 43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) invested $848K in research and development during fiscal year 2025.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) had a current ratio of 4.70 as of fiscal year 2025, which is generally considered healthy.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) had a liabilities-to-equity ratio of 0.20 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) had a return on assets of 36.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2025, Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) held $3.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.8M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
For every $1 of reported earnings, Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) used $1.59 of operating cash (-$4.8M OCF vs $3.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock (CYCCP) reported an operating loss of $8.4M against $62K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.